Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash & Equivalents: 2018-2024

Historic Cash & Equivalents for Neurogene (NGNE) over the last 4 years, with Dec 2024 value amounting to $136.6 million.

  • Neurogene's Cash & Equivalents rose 6.56% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year increase of 6.56%. This contributed to the annual value of $136.6 million for FY2024, which is 7.84% down from last year.
  • As of FY2024, Neurogene's Cash & Equivalents stood at $136.6 million, which was down 7.84% from $148.2 million recorded in FY2023.
  • Over the past 5 years, Neurogene's Cash & Equivalents peaked at $148.2 million during FY2023, and registered a low of $136.6 million during FY2024.
  • In the last 2 years, Neurogene's Cash & Equivalents had a median value of $142.4 million in 2023 and averaged $142.4 million.
  • Data for Neurogene's Cash & Equivalents shows a maximum YoY dropped of 7.84% (in 2024) over the last 5 years.
  • Over the past 2 years, Neurogene's Cash & Equivalents (Yearly) stood at $148.2 million in 2023, then declined by 7.84% to $136.6 million in 2024.